BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garbuzenko DV. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol 2015; 21(20): 6117-6126 [PMID: 26034348 DOI: 10.3748/wjg.v21.i20.6117] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. World J Gastroenterol 2019;25:3738-52. [PMID: 31391769 DOI: 10.3748/wjg.v25.i28.3738] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
2 Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. World J Gastroenterol. 2018;24:3738-3748. [PMID: 30197479 DOI: 10.3748/wjg.v24.i33.3738] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kumar A, Khan NM, Anikhindi SA, Sharma P, Bansal N, Singla V, Arora A. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India. World J Gastroenterol 2017;23:687-96. [PMID: 28216976 DOI: 10.3748/wjg.v23.i4.687] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chiu HW, Hua KF. Hepatoprotective Effect of Wheat-Based Solid-State Fermented Antrodia cinnamomea in Carbon Tetrachloride-Induced Liver Injury in Rat. PLoS One 2016;11:e0153087. [PMID: 27046059 DOI: 10.1371/journal.pone.0153087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
6 Zhang Y, Mao DF, Zhang MW, Fan XX. Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension. World J Gastroenterol 2017;23:8044-52. [PMID: 29259380 DOI: 10.3748/wjg.v23.i45.8044] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: An update and review of the literature. World J Hepatol. 2017;9:1197-1204. [PMID: 29152039 DOI: 10.4254/wjh.v9.i31.1197] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
9 Kalambokis GN, Baltayiannis G, Christodoulou D. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis. World J Gastroenterol 2016;22:4786-8. [PMID: 27217711 DOI: 10.3748/wjg.v22.i19.4786] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Tetangco EP, Silva RG, Lerma EV. Portal hypertension: Etiology, evaluation, and management. Dis Mon 2016;62:411-26. [PMID: 27788916 DOI: 10.1016/j.disamonth.2016.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]